Address
:
[go:
up one dir
,
main page
]
Include Form
Remove Scripts
Accept Cookies
Show Images
Show Referer
Rotate13
Base64
Strip Meta
Strip Title
Session Cookies
Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q81086287)
Watch
English
Lung cancer
scientific article published on 01 January 2005
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
Lung cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
author name string
Giuseppe Giaccone
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
Egbert Smit
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
publication date
1 January 2005
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
published in
Cancer chemotherapy and biological response modifiers
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
volume
22
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
page(s)
413-442
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
cites work
Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sequential chemoradiotherapy versus radiotherapy in the management of locally advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined Therapy with Topotecan and Gemcitabine in Patients with Inoperable or Metastatic Non-small Cell Lung Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of vinorelbine, mitomycin C and cisplatin chemotherapy for advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience from a Single Institution
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I Study of Weekly Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0921-4410(04)22019-1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
PubMed publication ID
16110623
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16110623
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit